Wednesday, 14 October 2015
Hall D1 Foyer (Floor 3) (Coex Convention Center)
Joon Young Choi
,
St. Mary's Hospital, Seoul, South Korea
Objective Thymic stromal lymphopoietin (TSLP) is an epithelial-cell derived cytokine that may be important in initiating allergic inflammation. This study aimed to investigate whether TSLP reduced airway inflammation in a murine model of asthma. Methods. BALB/c mice were sensitized and challenged with ovalbumin (OVA), and the effect of TSLP on airway inflammation and airway hyperresponsiveness (AHR) was evaluated. Furthermore, we measured changes in various cytokines in the bronchoalveolar lavage (BAL) fluid when treated with TSLP Results. We observed that TSLP exert a negative regulation on OVA mediated allergic airway inflammation. TSLP treatment reduced total cell counts and eosinophil counts in BAL fluid and AHR to methacholine. The Th2 cytokines, such as IL-4, IL-5 and IL-13 in BAL fluid also decreased after TSLP treatments. Conclusions. These results suggest that TSLP has a therapeutic potential for allergic asthma through inhibition of Th2 cytokine production.